CMAB offers a fully integrated approach to the process development of antibodies and biologics. We combine scalable and adaptable development services with a proven history of scientific expertise to rapidly move DNA aequence from development to commercial manufacturing.

The appropriately segregated manufacturing facilities and Single-use equipment allow CMAB to handle multiple products in parallel while minimize risk of cross-contamination and allow rapid product change-over.

CMAB's Fill-Finish process service offers a dedicated state-of-the-art facility designed for clinical drug product.

We remain vigilant, ensuring all aspects of the process from concept to finished goods meet the highest global GMP standards inclusive of the NMPA, US FDA – 21CFR, European Medicines Agency, (Eudralex), World Health Organization (WHO), and harmonized PIC/s and ICH.